We found through the TCGA database that PLA2G4A is highly expressed in KRAS-mutated lung cancer cells (Supplementary Figure S1A), and cPLA2 may be a therapeutic target for KRAS-mutated lung cancer cells. This evidence concerns the gene KRAS and lung carcinoma.